Fallopian Tube Cancer Clinical Trials

500 clinical trials for Fallopian Tube Cancer across international registries, including 65 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) — RECRUITING · PHASE3
• A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. — RECRUITING · PHASE2
• Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer — RECRUITING · PHASE2
• Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) — RECRUITING · PHASE1
• Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer — RECRUITING · PHASE3
• Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer — RECRUITING · PHASE1
• A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors — RECRUITING · PHASE1
• A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors — RECRUITING · PHASE1
• A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy — RECRUITING · PHASE2
• Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer — RECRUITING · PHASE1
• Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers — RECRUITING · PHASE2
• An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib — RECRUITING · PHASE2
• Using Aspirin to Improve Immunological Features of Ovarian Tumors — RECRUITING · PHASE1
• Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) — RECRUITING · PHASE3
• A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01) — RECRUITING · PHASE3
• Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer — RECRUITING · PHASE1
• A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE) — RECRUITING · NA
• A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors — RECRUITING · PHASE1
• Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study — RECRUITING · NA
• ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer — RECRUITING · PHASE2
• A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies — RECRUITING · PHASE2
• Performance of SYMMCORA® vs. V-Loc® Suture Material in Patients Undergoing Laparoscopic Total Hysterectomy — RECRUITING
• Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer — RECRUITING · PHASE1
• Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors — RECRUITING · PHASE2
• A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer — RECRUITING · PHASE1
• Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery — RECRUITING · PHASE2
• The PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian Cancer — RECRUITING · PHASE1
• Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype — RECRUITING
• A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers — RECRUITING · PHASE1
• CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. — RECRUITING · PHASE2
• A PHASE 1B/2 OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RALUDOTATUG DERUXTECAN WITH OR WITHOUT OTHER ANTICANCER INVESTIGATIONAL AGENTS IN PARTICIPANTS WITH HIGH-GRADE SEROUS EPITHELIAL OVARIAN, PRIMARY PERITONEAL, OR FALLOPIAN TUBE CANCER WHO HAVE RELAPSED AFTER PRIOR PLATINUM-BASED CHEMOTHERAPY — RECRUITING · PHASE1
• A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab — RECRUITING · PHASE1
• Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer — RECRUITING · NA
• Study of AVZO-021 in Patients With Advanced Solid Tumors — RECRUITING · PHASE1
• Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer — RECRUITING · PHASE2
• Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer — RECRUITING · PHASE3
• A Beta-only IL-2 ImmunoTherapY Study — RECRUITING · PHASE1
• Personalised Timing of Interval Debulking Surgery in Advanced Ovarian Cancer — RECRUITING · PHASE2
• Personalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer — RECRUITING · PHASE2
• Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer — RECRUITING · PHASE3
• Specimen and Data Study for Ovarian Cancer Early Detection and Prevention — RECRUITING
• Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer — RECRUITING · PHASE2
• Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer — RECRUITING · PHASE2
• HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer — RECRUITING · PHASE2
• A PHASE 1, FIRST-IN-HUMAN, OPEN-LABEL, DOSE-ESCALATION AND EXPANSION STUDY OF IMGN151 (ANTI-FR¿ ANTIBODY-DRUG CONJUGATE) IN ADULT PATIENTS WITH RECURRENT ENDOMETRIAL CANCER AND RECURRENT, HIGH-GRADE SEROUS EPITHELIAL OVARIAN, PRIMARY PERITONEAL, OR FALLOPIAN TUBE CANCERS — RECRUITING · PHASE1
• Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer — RECRUITING · PHASE2
• Development and Management of Registry in Patients With Gynecologic Cancer in Korea — RECRUITING
• A PHASE 3 STUDY OF RELACORILANT IN COMBINATION WITH NAB-PACLITAXEL VERSUS NAB-PACLITAXEL MONOTHERAPY IN ADVANCED, PLATINUM-RESISTANT HIGH-GRADE EPITHELIAL OVARIAN, PRIMARY PERITONEAL, OR FALLOPIAN-TUBE CANCER (ROSELLA) — RECRUITING · PHASE3
• RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE 3 STUDY OF MIRVETUXIMAB SORAVTANSINE IN COMBINATION WITH BEVACIZUMAB VERSUS BEVACIZUMAB ALONE AS MAINTENANCE THERAPY FOR PATIENTS WITH FRA-HIGH RECURRENT PLATINUM-SENSITIVE EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCERS WHO HAVE NOT PROGRESSED AFTER SECOND-LINE PLATINUM-BASED CHEMOTHERAPY PLUS BEVACIZUMAB (GLORIOSA) — RECRUITING · PHASE3
• MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF CARBOPLATIN PLUS MIRVETUXIMAB SORAVTANSINE FOLLOWED BY MIRVETUXIMAB SORAVTANSINE CONTINUATION IN FOLATE RECEPTOR-ALPHA POSITIVE, RECURRENT PLATINUM-SENSITIVE, HIGH-GRADE EPITHELIAL OVARIAN, PRIMARY PERITONEAL OR FALLOPIAN TUBE CANCERS FOLLOWING 1 PRIOR LINE OF PLATINUM-BASED CHEMOTHERAPY — RECRUITING · PHASE2

Refine this search